Japan vs Latvia: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Japan
0.0%
in 2024
Latvia
0.0%
in 2024
Japan rank
143rd
Latvia rank
143rd
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Japan
- Latvia
How they compare
Japan currently reports 0.0% against 0.0% in Latvia, a difference of 0.0%.
Across all 10 years both countries report, Latvia has been ahead every year.
Japan ranks 143rd and Latvia ranks 143rd of 215 countries.
Latvia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Japan | Latvia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.0% | 0.1% | 0.0% | Latvia |
| 2020s | 0.0% | 0.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Japan or Latvia?
- Japan, at 0.0% against 0.0% in Latvia as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Japan and Latvia?
- 0.0%, with Japan ahead.
- How many years of comparable data are there for Japan and Latvia?
- 10 years are reported by both, from 2015 to 2024.
- How do Japan and Latvia rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Japan ranks 143rd and Latvia ranks 143rd of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.